Targeting siRNAs in cancer drug delivery

Mohammad A. Obeid, Alaa A.a. Aljabali, Walhan Alshaer, Nitin Bharat Charbe, Dinesh Kumar Chellappan, Kamal Dua, Saurabh Satija, Murtaza M. Tambuwala

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Small interfering RNA (siRNA) has been identified as a useful therapeutic resource in cancer therapy. Molecular manipulation with siRNA has been reported to have high therapeutic potential on the cells with excessive gene overexpression or caused by mutation. However, siRNA therapeutic approaches are pursuing effective and efficient delivery systems for in vivo applications due to the lack of stable, low cell uptake, and the high likelihood of function loss due to enzymatic degradation. The chapter comprises various approaches used to improve siRNA delivery focusing on nanoparticles with a common goal and superior effectiveness. Besides, this chapter discusses problems and prospects for creating safe and effective siRNA delivery systems in cancer therapy, focusing on nanoparticles. Similarly, it assesses the recent progress achieved by nanomaterials, including biodegradables, liposomes, polyplex, lipoplex, and dendrimers with the transmission of small interfering RNA (siRNA). The morphology, structure, and preparation of different nanoparticles and their strengths, along with the recent progress of siRNA carrier systems in preclinical and clinical research, are also addressed in detail.
Original languageEnglish
Title of host publicationAdvanced Drug Delivery Systems in the Management of Cancer
PublisherElsevier
Chapter35
Pages447-460
Number of pages13
ISBN (Print)9780323855037
DOIs
Publication statusPublished - 25 Jun 2021

Keywords

  • Cancer
  • Drug delivery

Fingerprint

Dive into the research topics of 'Targeting siRNAs in cancer drug delivery'. Together they form a unique fingerprint.

Cite this